Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1)

NCT03566238 is registered in ClinicalTrials.gov with Albireo as lead sponsor.

NCT NCT03566238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03566238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1)
Lead sponsor
Albireo
Phase
Phase 3
Overall status
Completed
Start date
May 16, 2018
Completion date
July 28, 2020
Enrollment
62 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

pfic1, pfic2